Related Experiment Video

Updated: Jun 24, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

[Association of NAT2 polymorphism with risks to develop psoriasis and various dermatological diseases in Moscow

Zh M Kozhekbaeva, O A Gra, V S Fadeev

    Molekuliarnaia Biologiia
    |April 2, 2009
    PubMed

    Insights

    Certain N-acetyltransferase 2 (NAT2) genotypes and lifestyle factors like smoking and alcohol consumption are linked to increased psoriasis risk in a Moscow population. These genetic variations influence how the body processes environmental toxins, potentially contributing to disease development.

    Area of Science:

    • Pharmacogenomics
    • Dermatology
    • Biochemistry

    Context:

    • N-acetyltransferase 2 (NAT2) is crucial for metabolizing genotoxic compounds.
    • Altered NAT2 activity correlates with increased susceptibility to multifactorial diseases, including psoriasis.
    • Genetic variations in NAT2 may influence psoriasis development and severity.

    Purpose:

    • To investigate the association between NAT2 single nucleotide polymorphisms (SNPs) and psoriasis risk in a Moscow population.
    • To identify specific NAT2 genotypes and lifestyle factors that contribute to psoriasis development.
    • To analyze the prevalence of NAT2 genotypes and phenotypes in psoriasis patients compared to healthy individuals.

    Summary:

    • A NAT2-biochip was developed and tested on 279 DNA samples from individuals in Moscow.
    • Six significant SNPs were identified for European populations, but no direct genotype association was found in the psoriasis group.
    • Increased frequency of slow acetylation phenotype was observed in type II psoriasis patients and those with normosthenic constitution.
    • Specific NAT2 genotypes (e.g., 341C/C, 481T/T, 803G/G) were associated with smoking and alcohol consumption.
    • Certain genotypes (e.g., 341T/T, 481C/C, 590A/-, 803A/A) showed increased frequency in patients with adverse drug reactions.

    Impact:

    • Identifies specific NAT2 genotypes and lifestyle factors as potential risk factors for psoriasis in the studied population.
    • Highlights the role of pharmacogenetics in understanding multifactorial diseases like psoriasis.
    • Provides insights into personalized medicine approaches for psoriasis risk assessment and management.

    More Related Videos

    Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

    Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

    Published on: April 4, 2018

    Related Concept Videos

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

    Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

    Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Drug toxicity: Idiosyncratic Reactions01:16

    Drug toxicity: Idiosyncratic Reactions

    Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
    Single Nucleotide Polymorphisms-SNPs01:05

    Single Nucleotide Polymorphisms-SNPs

    A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...